Navigation Links
New papers offer insights into process of malarial drug resistance
Date:11/26/2008

Malaria, one of the oldest diseases known to man, has shown no signs of slowing down as it ages. More than 1 million children die from malaria in sub-Saharan Africa each year, and in areas along the Thailand/Cambodian border multiple drug-resistant strains of the disease are becoming commonplace.

With the previously mainstay antimalarial drug chloroquine nearly ineffective due to drug resistance and traditional public health approaches such as mosquito netting offering uneven results, two new papers by University of Notre Dame biologist Michael Ferdig suggest that the means of combating this old foe may lie in the new tools of genomics and bioinformatics.

In the papers, Ferdig points out that development of the malaria parasite Plasmodium falciparum in the blood is driven by a number of different genes expressed at different times and at different levels. Exactly what influences such transcriptional changes remains elusive, particularly in regard to important phenotypes like drug resistance.

Ferdig and his collaborators combined classical genetics with cutting-edge genomic methods to illuminate previously unrecognized transcriptional complexity and variation in Plasmodium falciparum and possibly master regulators within large copy number variants that contribute to the drug-resistant phenomena in malaria parasites.

By uncovering the genetic "architecture" of numerous drug responses and identifying key regulators that control these responses, Ferdig hopes to map new approaches to conquering drug resistant malarial genes.

One paper from the Ferdig lab appeared in the journal PLoS Biology. The second, in collaboration with Tim Anderson at Southwest Biomedical Research Foundation, appeared in PLoS Genetics.


'/>"/>

Contact: Michael Ferdig
ferdig.1@nd.edu
574-631-9973
University of Notre Dame
Source:Eurekalert

Page: 1

Related biology news :

1. U.S. IEEE members to report on Sci-Tech at California newspapers
2. A gentle touch for better control, a quantum mechanical con, and milestone PRL papers
3. Light pollution offers new global measure of coral reef health
4. Ripple effect: Water snails offer new propulsion possibilities
5. Commercial aquatic plants offer cost-effective method for treating wastewater
6. Advance offers revolution in food safety testing
7. Worm genome offers clues to evolution of parasitism
8. Stantum Offering Demo, Evaluation & Development Board Based on Its Patented Resistive Multi-Touch Technology
9. Combining advanced medical and information technologies offers pathway to lower health care costs
10. New study offers solution to global fisheries collapse
11. Giant grass offers clues to growing corn in cooler climes, researchers report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... commerce market announces a revised version of one of its first ... air on CNBC in New York , ... San Francisco metro areas.    ... ability to replace all the cards in your wallet and keep ...
(Date:6/30/2015)... NEW YORK , June 30, 2015 To ... biometric security provider HYPR Corp. announced today the addition of ... will serve as board advisor and David Raviv ... to the team underscore HYPR Corp.,s commitment to providing the ... , Dimitri Sirota co-founded Layer 7 Technologies, a ...
Breaking Biology News(10 mins):Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... at Boston Children,s Hospital have found that microscopic particles ... protect the fragile lungs of premature babies from serious ... The findings explain earlier research suggesting that ... stem cells (MSCs) could help reduce lung injury and ...
... scientists have built the first solar cell made entirely of ... photovoltaic devices today. The results are published in ... Nano . "Carbon has the potential to deliver high ... Bao, a professor of chemical engineering at Stanford. "To ...
... ARBORNisin, a common food preservative, may slow or stop squamous ... found. What makes this particularly good news ... Health Organization approved nisin as safe for human consumption decades ... at the University of Michigan School of Dentistry. ...
Cached Biology News:Microscopic packets of stem cell factors could be key to preventing lung disease in babies 2Microscopic packets of stem cell factors could be key to preventing lung disease in babies 3Stanford scientists build the first all-carbon solar cell 2Stanford scientists build the first all-carbon solar cell 3Common food preservative may slow, even stop tumor growth 2
(Date:7/30/2015)... , ... July 30, 2015 , ... The 2015 Market ... study on the current state of the global Propanol market with a focus on ... BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG ...
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative ... study of its canine osteoarthritis stem cell product, currently under development for FDA ... and will be marketed in the US by Aratana. This product, termed AT-016, ...
(Date:7/30/2015)... 2015   Senomyx , Inc. (NASDAQ: SNMX ... to discover, develop, and commercialize novel flavor ingredients for ... financial results for the second quarter 2015. ... remain on track to achieve our commercial and financial ... of the Company. "Since our last quarterly earnings report, ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... ROSA, Calif., Sept. 29 Osseon™ Therapeutics, Inc., ... invasive treatments for degenerative bone disease and osteo-traumatic ... significant milestone in vertebral compression fracture (VCF) treatments ... Michael Lyster, Chief Medical Officer of Osseon, commented, ...
... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; ... var shortURL = ""; BitlyCB.alertResponse = function(data) { ... the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key ...
... Mich., Sept. 29 GeneGo, Inc., the leading systems ... the OMIC repository and analysis field, announced today integration ... data mining suite. Array Studio, Omicsoft,s software ... and visualization tools for high dimensional quantification data (OMICS ...
Cached Biology Technology:Osseon™ Treats 1,000 Patients With Osseoplasty™ Procedure for Vertebral Compression Fractures 2Tianyin Reports Record Fiscal 2010 Financial Results 2Tianyin Reports Record Fiscal 2010 Financial Results 3Tianyin Reports Record Fiscal 2010 Financial Results 4Tianyin Reports Record Fiscal 2010 Financial Results 5Tianyin Reports Record Fiscal 2010 Financial Results 6Tianyin Reports Record Fiscal 2010 Financial Results 7Tianyin Reports Record Fiscal 2010 Financial Results 8Tianyin Reports Record Fiscal 2010 Financial Results 9Tianyin Reports Record Fiscal 2010 Financial Results 10Tianyin Reports Record Fiscal 2010 Financial Results 11Tianyin Reports Record Fiscal 2010 Financial Results 12Tianyin Reports Record Fiscal 2010 Financial Results 13GeneGo and Omicsoft Collaborate on Pathway Analysis for Next Generation Sequence Data 2
... long and short-term enriched housing for nonhuman ... quarantine and non-quarantine settings on a per ... utilizing our state-of-the-art social housing and nursery ... on site CDC quarantine facilities. Primate ...
... some the things youll be telling others after ... by Erica Golemis, One look at the table ... topics in protein interaction will tell you immediately ... a part of your personal protein chemistry library. ...
... acid gel stain has bright fluorescence when bound ... it ideal for detecting dsDNA in gels using ... Green I nucleic acid stain has also ... assays and bandshift assays. A 500 µL unit ...
... Persistent Analysis Environment 2) Dot plot, ... 3) Software Compensation 4) Cell Cycle ... Platform 7) Intelligent batch generation of graphs ... 9) Single drag-and-drop operations to perform complex ...
Biology Products: